CVRx to Showcase Innovative Solutions at Major Conference
CVRx, Inc. (NASDAQ: CVRX), a dynamic and innovative medical device company, is making waves in the healthcare field, particularly in the area of neuromodulation for cardiovascular diseases. The company has announced participation in a significant event, the Piper Sandler 37th Annual Healthcare Conference, where they will engage in a fireside chat aimed at sharing insights on their latest advancements. This event is scheduled for a day in December.
Upcoming Participation at the Conference
The management team of CVRx is set to present during a fireside chat at precisely 2:00 PM (ET) via an online webcast. This discussion promises to provide attendees with an inside look at the company’s strategy and innovations that can potentially impact patient care, especially for those dealing with heart failure.
Introducing Barostim™: A Breakthrough Technology
Barostim™ stands out as CVRx's flagship medical technology, earning recognition as the first FDA-approved neuromodulation therapy specifically designed to alleviate symptoms associated with heart failure. The device operates by delivering electrical pulses to baroreceptors located in the carotid artery, effectively aiming to restore balance in the autonomic nervous system. This approach is crucial in managing heart failure, a condition that affects numerous individuals worldwide.
Regulatory Achievements and Impact
Barostim has not only received FDA Breakthrough Device designation but is also approved for heart failure treatment in the United States. In addition, it complies with EU Medical Device Regulations (MDR) and has secured CE Mark approval, affirming its efficacy in both heart failure and resistant hypertension across the European Economic Area. These milestones underline CVRx's commitment to enhancing the quality of life for patients globally.
Connecting with CVRx
Interested parties can tune into the live audio webcast to hear directly from the management about upcoming initiatives and the impact of products like Barostim on patient care. As the healthcare landscape evolves, CVRx remains at the forefront, ready to introduce solutions that tackle some of the most pressing cardiovascular challenges.
Investor Inquiries and Contact Information
For further inquiries regarding the conference participation or product information, investors and interested stakeholders can reach out to CVRx via the investor relations team, comprising Mark Klausner and Mike Vallie at ICR Healthcare. They are available at 443-213-0501, and inquiries can also be directed through their email address.
Frequently Asked Questions
What is the focus of CVRx, Inc.?
CVRx, Inc. is dedicated to developing and commercializing neuromodulation solutions specifically for patients suffering from cardiovascular diseases.
What is Barostim™?
Barostim™ is an innovative medical device approved by the FDA that uses neuromodulation to improve symptoms in heart failure patients.
When is the Piper Sandler Healthcare Conference taking place?
The conference will occur in December, with CVRx participating in a two-hour session that includes a fireside chat.
How can I access the CVRx webcast?
The webcast for the fireside chat will be available on the investor relations section of CVRx's website during the event.
How can I contact CVRx for more information?
For inquiries, you can contact Mark Klausner or Mike Vallie at ICR Healthcare for investment-related questions or reach out to the media contact Emily Meyers directly.
